Claims for Patent: 11,730,706

Summary for Patent: 11,730,706

Title:	Treatment of depression in certain patient populations
Abstract:	This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prologation.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US18/158,268
Patent Claims:	1. A method of treating major depressive disorder in a human patient who has moderate renal impairment, comprising administering once daily, by mouth, one tablet containing about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide to the human patient who has moderate renal impairment and is experiencing major depressive disorder, wherein the dextromethorphan hydrobromide is in an immediate-release formulation, wherein the bupropion hydrochloride is in an extended-release formulation, and wherein the tablet is a bilayer tablet. 2. A method of treating major depressive disorder in a human patient who has moderate renal impairment, comprising administering once daily, by mouth, one tablet containing about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide to the human patient who has moderate renal impairment and is experiencing major depressive disorder, wherein the dextromethorphan hydrobromide is in an immediate-release formulation, wherein the bupropion hydrochloride is in an extended-release formulation, and wherein the Tmax of dextromethorphan is about 3 hours. 3. The method of claim 2, wherein steady state plasma concentrations of dextromethorphan and bupropion are achieved within 8 days, and wherein the accumulation ratio for dextromethorphan at steady state is about 20 based on the Cmax. 4. The method of claim 2, wherein steady state plasma concentrations of dextromethorphan and bupropion are achieved within 8 days, and wherein the accumulation ratio for dextromethorphan is about 32 based on the AUC0-12. 5. The method of claim 2, wherein the once-daily administration avoids the human patient having an about 2.2-fold increase in AUC0-12 of dextromethorphan as compared to the AUC0-12 of dextromethorphan that would result from twice daily administration of the tablet for 8 days to a human patient who has no renal impairment. 6. The method of claim 2, wherein the once-daily administration avoids the patient having an about 2.1-fold increase in Cmax of dextromethorphan as compared to the Cmax of dextromethorphan that would result from twice daily administration of the tablet for 8 days to a human patient who has no renal impairment. 7. The method of claim 2, wherein the once-daily administration avoids the human patient having an about 1.8-fold increase in AUC0-12 of bupropion as compared to the AUC0-12 of bupropion that would result from twice daily administration of the tablet for 8 days to a human patient who has no renal impairment. 8. The method of claim 2, wherein the once-daily administration avoids the patient having an about 1.9-fold increase in Cmax of bupropion as compared to the Cmax of bupropion that would result from twice daily administration of the tablet for 8 days to a human patient who has no renal impairment. 9. A method of treating major depressive disorder in a human patient who has moderate renal impairment, comprising administering a daily dose of: (i) about 105 mg of bupropion hydrochloride and (ii) about 45 mg of dextromethorphan hydrobromide to the human patient who has moderate renal impairment and is experiencing major depressive disorder, and wherein the human patient has an estimated glomerular filtration rate that is between about 30 mL/min/1.72 m2 and 59 mL/min/1.72 m2. 10. The method of claim 9, wherein the administering is achieved by once daily administration, by mouth, of one tablet containing about 105 mg of bupropion hydrochloride and about 45 mg of dextromethorphan hydrobromide. 11. The method of claim 10, wherein the dextromethorphan hydrobromide is in an immediate-release formulation. 12. The method of claim 11, wherein the bupropion hydrochloride is in an extended-release formulation. 13. The method of claim 12, wherein the tablet is a bilayer tablet. 14. The method of claim 12, wherein the Tmax of dextromethorphan is about 3 hours. 15. The method of claim 12, wherein steady state plasma concentrations of dextromethorphan and bupropion are achieved within 8 days, and wherein the accumulation ratio for dextromethorphan at steady state is about 20 based on the Cmax. 16. The method of claim 12, wherein steady state plasma concentrations of dextromethorphan and bupropion are achieved within 8 days, and wherein the accumulation ratio for dextromethorphan at steady state is about 32 based on the AUC0-12. 17. The method of claim 12, wherein the once-daily administration avoids the human patient having an about 2.2-fold increase in AUC0-12 of dextromethorphan as compared to the AUC0-12 of dextromethorphan that would result from twice daily administration of the tablet for 8 days to a human patient who has no renal impairment. 18. The method of claim 12, wherein the once-daily administration avoids the patient having an about 2.1-fold increase in Cmax of dextromethorphan as compared to the Cmax of dextromethorphan that would result from twice daily administration of the tablet for 8 days to a human patient who has no renal impairment. 19. The method of claim 12, wherein the once-daily administration avoids the human patient having an about 1.8-fold increase in AUC0-12 of bupropion as compared to the AUC0-12 of bupropion that would result from twice daily administration of the tablet for 8 days to a human patient who has no renal impairment. 20. The method of claim 12, wherein the once-daily administration avoids the patient having an about 1.9-fold increase in Cmax of bupropion as compared to the Cmax of bupropion that would result from twice daily administration of the tablet for 8 days to a human patient who has no renal impairment.